Mechanism of Action of the LAT1 Inhibitor Being Developed by Our Company
NEWS
-
- 2026.08.14
-
J-Pharma’s LAT1 Inhibitor Development Included in University Office of Technology Commercialization’s FY2026 Annual Report — Report Highlights Progress in Clinical Development—
-
- 2026.08.12
-
Post Hoc Analysis of Nanvuranlat (JPH203) in Advanced Biliary Tract Cancer Published in Cancers — Exploratory Findings to Be Prospectively Evaluated in the Global Phase III Beacon-BTC Study —
-
- 2026.08.04
-
J-Pharma President and CEO Masuhiro Yoshitake Featured in BioSpectrum Asia Interview
